36. An isolated polypeptide of claim 35 comprising at least 50 contiguous amino acid residues of SEQ ID NO:2.

37. An isolated polypeptide of claim 36 comprising amino acids 2 to 92 in SEQ ID NO:2.

38. An isolated polypeptide of claim 37 comprising amino acids 1 to 92 in SEQ ID NO:2.

39. An isolated polypeptide of claim 35 further comprising a heterologous polypeptide sequence.

40. An isolated polypeptide comprising at least 30 contiguous amino acid residues of the polypeptide encoded by the human cDNA contained in ATCC Deposit No. 97304.

41. An isolated polypeptide comprising at least 50 contiguous amino acid residues of the polypeptide encoded by the human cDNA contained in ATCC Deposit No. 97304.

42. An isolated polypeptide comprising the mature polypeptide encoded by the human cDNA contained in ATCC Deposit No. 97304.

43. An isolated polypeptide comprising the full length polypeptide encoded by the human cDNA contained in ATCC Deposit No. 97304.

44. The isolated polypeptide of claim 40 further comprising a heterologous polypeptide sequence.

45. An isolated protein produced by the method comprising:

(a) culturing a host cell under conditions suitable to produce the protein molecule of claim 35, and

(b) recovering said protein molecule.

46. An isolated protein produced by the method comprising:

(a) culturing a host cell under conditions suitable to produce the protein molecule of claim 36; and

(b) recovering said protein molecule.

47. An isolated protein produced by the method comprising:

(a) culturing a host cell under conditions suitable to produce the protein molecule of claim 37; and

(b) recovering said protein molecule.

48. An isolated protein produced by the method comprising:

(a) culturing a host cell under conditions suitable to produce the protein molecule of claim 38; and

(b) recovering said protein molecule.

49. An isolated protein produced by the method comprising:

(a) culturing a host cell under conditions suitable to produce the protein molecule of claim 39, and

(b) recovering said protein molecule.

50. An isolated protein produced by the method comprising:

(a) culturing a host cell under conditions suitable to produce the protein molecule of claim 40; and

(b) recovering said protein molecule.

51. An isolated protein produced by the method comprising:

(a) culturing a host cell under conditions suitable to produce the protein molecule of claim 41; and

(b) recovering said protein molecule.

52. An isolated protein produced by the method comprising:

(a) culturing a host cell under conditions suitable to produce the protein molecule of claim 42; and

(b) recovering said protein molecule.

53. An isolated protein produced by the method comprising:

(a) culturing a host cell under conditions suitable to produce the protein molecule of claim 43, and

(b) recovering said protein molecule.

54. An isolated protein produced by the method comprising:

(a) culturing a host cell under conditions suitable to produce the protein molecule of claim 44, and

(b) recovering said protein molecule.

55. An isolated polypeptide comprising: a mature polypeptide having an amino acid sequence encoded by an isolated polynucleotide comprising a polynucleotide having about 95% identity to a member selected from the group consisting of :

(a) a polynucleotide encoding a polypeptide comprising amino acids 1 to 92 of SEQ ID NO: 2;

(b) a polynucleotide encoding a polypeptide comprising amino acids 2 to 92 of SEQ ID NO:2; and

(c) the human cDNA contained in ATCC Deposit No. 97304; and a complement of (a), (b), or (c).

56. A composition comprising the protein molecule of claim 35.

57. A compound which activates or inhibits the activity of the isolated protein molecule of claim 35 by activating or inhibiting a receptor for said polypeptide.

58. An isolated polypeptide comprising a fragment of contiguous amino acid residues of SEQ ID NO:2.

59. An isolated polypeptide of claim 58 further comprising a heterologous polypeptide sequence. –

REMARKS

Amendment of the Specification

The amendment to the specification corrects the address of the ATCC depository. Therefore, no new matter will be added to the specification if this address is corrected. Applicants respectfully request that the amendment to the specification be entered.

New Claims

Support for the new claims 35-55 can be found throughout the specification and originally filed claims. More particularly, new claims 35-55 find support in the original claims 20-24 and 1-19. Support for new claim 57 is found in original claims 26-27 and 34. The language in new claims 35-55 closely parallels the language of the polynucleotide claims deemed allowable in parent application U.S. Serial No. 08/761,289. Support for new claim 56 is found, for example, in the paragraph